Posted on 06/08/2010 in Pharmaceutical Company Product News Shire has published data from new clinical trials of Firazyr (icatibant), its new drug for the treatment of hereditary angioedema (HAE) attacks.
The pharmaceutical company recently conducted a pair of phase III clinical trials which evaluated the efficacy of the drug among adult patients with type 1 or type 2 HAE, both in isolation and compared to placebo.
It was found that Shire's therapy was able to demonstrate effectiveness in reducing abdominal and cutaneous pain, as well as providing relief against laryngeal attacks.
Professor Marco Cicardi of the department of internal medicine at the University of Milan said these benefits were important due to the "unpredictability and variability" of the disease.
He added: "The publication of this study shows the subcutaneous injection of icatibant to be an effective and well-tolerated treatment for acute attacks of HAE in adults."
Earlier this week, Shire published its financial report for the third quarter, announcing a 35 per cent year-on-year increase in revenues. Other news stories from 06/08/2010
Read more in the Zenopa News Archive
How this news is generated
|
